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CASE REPORT / OLGU SUNUMU
A case of colistin-induced fixed drug eruption
Kolistine bağlı fiks ilaç erüpsiyonu olgusu
İsmail Necati Hakyemez1, Abdulkadir Küçükbayrak2, Aslıhan Burcu Yıkılgan2, Elif Sultan Bolaç3,
Nebil Yıldız3, Çetin Boran4, Hayrettin Akdeniz2
ÖZET
Fiks ilaç erüpsiyonu (FİE) etyolojisinde başta antimikrobi-
yaller olmak üzere çeşitli ilaçlar rol almaktadır. Klinik görü-
nümü, ilaca bağlı gelişen bir reaksiyon için oldukça tipiktir. 
Literatürde, kolistine bağlı gelişen fiks ilaç erüpsiyonu ol-
gusu bildirilmemiştir. Acinetobacter pnömonisi nedeniyle 
kolistin kullanılan 83 yaşındaki bir erkek hastada ortaya 
çıkan fiks ilaç erüpsiyonu, çok nadir görülmesi açısından 
sunulmuştur. FİE ayırıcı tanısında kolistinin yer alabilece-
ği akılda tutulmalıdır.
Anahtar kelimeler: Fiks ilaç erüpsiyonu, etyoloji, kolistin
ABSTRACT
Several medicines, especially antimicrobials, play a role 
in the etiology of fixed drug eruption (FDE). The clinical 
manifestation  is  quite  typical  for  a  drug-induced  reac-
tion. FDE which developed in an 83-year-old male patient 
who has been administered colistin due to Acinetobacter 
pneumonia is presented here since it is very rarely seen. 
Therefore colistin should also be considered in the dif-
ferential diagnosis of FDE. J Clin Exp Invest 2013; 4 (3): 
374-376
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INTRODUCTION
Antibiotics,  antifungal  drugs,  analgesics,  anticon-
vulsants and sedatives are known to play a role in 
etiology of fixed drug eruption. Among antibiotics, 
trimethoprim-sulfamethoxazole  and  tetracyclines 
are the most frequently accused drugs [1,2]. Colis-
tin is a polymyxin group antibiotic used for treatment 
of the infections emerging with multi-resistant gram 
negative bacilli. Besides serious side effects such 
as  nephrotoxicity  and  neurotoxicity,  it  may  rarely 
lead to itching and skin rashes [3]. FDE which de-
veloped in an 83 years old male patient who has 
been  administered  colistin  due  to  Acinetobacter 
pneumonia is presented. 
CASE
An  83-year-old  male  patient  was  admitted  to  the 
hospital for the diagnosis of cerebrovascular occlu-
sion. Bilateral diffuse rales were auscultated in his 
physical examination and infiltrations were detected 
in  bilateral  lower  zones  on  the  chest  radiograph 
of  the  patient  who  developed  symptoms  of  fever 
and sputum. Because of Acinetobacter baumannii 
growth in the culture of sputum, the patient was put 
on intravenous  and inhaler  colistimethate  sodium 
(prodrug form of colistin) (Colimycin®) therapy with 
the diagnosis of pneumonia. The patient developed 
a  sharply  circumscribed,  annular,  erythematous 
hemorrhagic bullous skin lesion of 3x2 cm in size 
in the anterior abdominal wall on the second day of 
the treatment, and it turned into a hyperpigmented 
lesion on the seventh day (Figure 1). No any other 
skin symptom was found in the patient. Skin biopsy 
was carried out from the lesion by the dermatology 
department with the provisional diagnoses of trau-
matic bulla and FDE. Colistin was continued for one 
week because of the severe pneumonia. Pathologi-
cal examination of the lesion was consistent with 
the diagnosis of fixed drug eruption (Figure 2). The 
patient was diagnosed with fixed drug based on the 
clinic  and  pathologic  findings.  Fusidic  acid-  beta-
methasone valerate (fucicort®) cream was admin-
istered topically.Hakyemez et al. Colistin-induced fixed drug eruption 375
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Figure 1.  Sharply  circumscribed,  annular  and  hemor-
rhagic lesion in the anterior abdominal wall
Figure 2. Separation at the level of dermoepidermal junc-
tion, confluent epidermal necrolysis, intraepidermal lym-
phocytes and erythrocytes on the edematous ground in 
the subepidermal area (H&E, x200)
DISCUSSION
Clinical  manifestation  of  FDE  is  quite  pathogno-
monic for a drug-induced reaction [4]. In FDE, le-
sion  is  typically  sharply  circumscribed,  round  or 
oval, reaching up to 10 cm in diameter, purplish and 
mildly swollen from the skin. In general, postlesional 
pigmentation remains at the site of healing lesions. 
Often it is in the form of single lesion, but in some 
cases a large number of lesions may be seen and 
generalized FDE may even develop [1]. Antibody-
dependent cellular cytotoxicity plays an important 
role in the pathogenesis of FDE. In addition, it may 
also be associated with genetic factors [5]. 
The most accused agents in FDE include an-
timicrobials, non-steroidal anti-inflammatory drugs, 
sedatives, quinine and oral contraceptives. Among 
antimicrobials; tetracyclines, sulfonamides, penicil-
lins and metronidazole are accused in the etiology. 
FDE generally emerges between 30 minutes and 
16 hours after the drug intake, and occasionally this 
duration may be prolonged up to 48 hours. Although 
skin lesions are usually asymptomatic, sometimes 
they may painful, and burning. The lesions persist 
if the drug is continued and disappear within sev-
eral weeks after it is discontinued. If the responsible 
drug is taken again, lesions may repeat in the same 
site. The genital skin is the most involved region, but 
anywhere in the body may be affected [6]. In our pa-
tient, the lesion emerged in the anterior abdominal 
wall. Drug reactions are seen more frequently in the 
elderly due to using a large number of drugs [7]. Our 
patient was in the geriatric age group.
Diagnosis of the disease is usually established 
with typical appearance of the lesion. Histopatho-
logical examination is helpful for the diagnosis. In 
the biopsy made from the lesion; degeneration of 
the basal layer, edema in the papillary dermis and 
subepidermal  bulla  formation,  diffuse  lymphocytic 
infiltration in the dermoepidermal junction accom-
panied  by  eosinophils  and  necrotic  keratinocytes 
are found [8]. In our case, the biopsy carried out 
from the lesion was consistent with FDE. For the 
confirmation of the diagnosis, systemic oral provo-
cation tests can be performed, but these tests are 
not recommended by some authors due to the risk 
of generalized bullous eruption. Instead, topical and 
intradermal provocation tests are recommended [9].
Colistin is a polymyxin group antibiotic acting 
by injuring the cytoplasmic membrane. Colistimeth-
ate sodium is the prodrug form of colistin and is in-
active. It acts by turning into colistin after taken into 
the body. Mild itching may be seen in 20% of pa-
tients in taken colistimethate sodium, which doesn’t 
require the drug to be discontinued. This is resulted 
from the histamine-releasing effects of polymyxins. 
Rarely, contact dermatitis, macular rash, urticaria, 
ototoxicity, drug fever and gastrointestinal disorders 
may occur during the treatment [10]. 
The most effective approach to the treatment of 
FDE is discontinuation of the drug. In addition, topi-
cal corticosteroids can be applied in the non-eroded 
lesions,  wet  dressing  plus  topical  corticosteroids 
can be administered in the eroded lesions, and sys-
temic corticosteroid therapy may be given for about 
two weeks in the patients with diffuse involvement 
[1,8].  In  our  patient;  we  continued  to  the  colistin 
therapy for one week due to severe pneumonia. In Hakyemez et al. Colistin-induced fixed drug eruption 376
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addition, a clinical response of FDE was achieved 
with topical supportive therapy.
Colistin is often the only option in multidrug-re-
sistant nosocomial Acinetobacter infections. Thus, it 
is the most preferred antimicrobial in the treatment. 
To the best of our knowledge, there is no published 
report  of  colistin-induced  FDE  in  the  literature. 
Therefore, among the antimicrobial agents accused 
in the etiology of FDE, colistin should definitely be 
considered in the differential diagnosis.
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